公开(公告)号：US20240156787A1

公开(公告)日：2024-05-16

申请号：US18421405

申请日：2024-01-24

申请人： SCIENTURE, INC.

发明人： Bhavya Teja KOLLA ,  Rahul SURANA ,  Suketu SANGHVI ,  Jigar BHATT

IPC分类号： A61K31/4178 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K31/4178 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

摘要： The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

公开(公告)号：US11980219B2

公开(公告)日：2024-05-14

申请号：US17040232

申请日：2019-04-08

申请人： Philip Morris Products S.A.

发明人： Sebastien Capelli ,  Farideh Goudarzi ,  Timothy King ,  Jean-Yves Vollmer ,  Gerard Zuber

IPC分类号： A24B15/16 ,  A24B15/167 ,  A24B15/32 ,  A24B15/40 ,  A61K9/00 ,  A61K9/06 ,  A61K31/465 ,  A61K36/185 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

CPC分类号： A24B15/167 ,  A24B15/32 ,  A24B15/403 ,  A61K9/007 ,  A61K9/06 ,  A61K31/465 ,  A61K36/185 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

摘要： A composition is provided, including a gelling agent forming a solid medium, glycerol dispersed in the solid medium, and nicotine dispersed in the glycerol, the composition being a stable gel phase.

公开(公告)号：US20240148818A1

公开(公告)日：2024-05-09

申请号：US18518134

申请日：2023-11-22

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Zuguo Liu ,  Yufen Zhao ,  Caihong Huang ,  Yang Wu ,  Guo Tang ,  Yan Liu ,  Pengxiang Xu

IPC分类号： A61K38/05 ,  A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/36 ,  A61P27/04

CPC分类号： A61K38/05 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/14 ,  A61K47/186 ,  A61K47/36 ,  A61P27/04

摘要： The invention relates to an ophthalmic pharmaceutical composition and its preparation methods and applications, wherein the pharmaceutical composition comprises of L-Alanyl-L-Glutamine suspended or dissolved in an isoosmotic solution suitable for human eyes, and has the advantages causing minimal irritation, with high stability and a good safety profile, and which can be used for relieving dry eye disease (DED) symptoms and/or improving and/or treating DED.

公开(公告)号：US11974986B2

公开(公告)日：2024-05-07

申请号：US17386138

申请日：2021-07-27

申请人： ORASIS PHARMACEUTICALS LTD.

发明人： Claes Feinbaum ,  Franc Salamun ,  Sudhir Patel

IPC分类号： A61K31/4178 ,  A61K9/00 ,  A61K31/133 ,  A61K31/196 ,  A61K31/365 ,  A61K31/407 ,  A61K31/728 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K31/4178 ,  A61K9/0048 ,  A61K31/133 ,  A61K31/196 ,  A61K31/365 ,  A61K31/407 ,  A61K31/728 ,  A61K47/36 ,  A61K47/38 ,  A61K31/4178 ,  A61K2300/00 ,  A61K31/196 ,  A61K2300/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/133 ,  A61K2300/00 ,  A61K31/728 ,  A61K2300/00 ,  A61K31/365 ,  A61K2300/00

摘要： The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

公开(公告)号：US20240139235A1

公开(公告)日：2024-05-02

申请号：US18279039

申请日：2022-03-14

申请人： PHARMANUTRA S.P.A.

发明人： Andrea LACORTE ,  Germano TARANTINO ,  Elisa BRILLI

IPC分类号： A61K33/26 ,  A61K33/42 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61P1/04

CPC分类号： A61K33/26 ,  A61K33/42 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61P1/04

摘要： The present invention relates to an iron-based formulation and compositions thereof for use in a method for the treatment of a gastrointestinal inflammation, in a therapeutic or non-therapeutic treatment of an iron deficiency by administering said formulation to a subject, wherein said iron formulation is capable of reducing (or maintaining constant) the amount of pathogenic bacteria present in the gut microbiota of the treated subject and, preferably, also capable of increasing the variety of the gut microbiota of the treated subject.

公开(公告)号：US20240139097A1

公开(公告)日：2024-05-02

申请号：US18405864

申请日：2024-01-05

申请人： Boston Scientific Scimed, Inc.

发明人： Joseph T. Delaney, JR. ,  Samuel Raybin ,  John Kummailil ,  Matthew B. Hollyer

IPC分类号： A61K9/00 ,  A61K47/02 ,  A61K47/36

CPC分类号： A61K9/0019 ,  A61K47/02 ,  A61K47/36 ,  A61B5/6871

摘要： The present disclosure relates to injectable compositions sterile injectable fluid compositions comprising a polysaccharide having a color in the visible spectrum, methods of forming the same, kits containing the same, and methods for performing agent-assisted procedures in a patient using the same.

公开(公告)号：US11969438B1

公开(公告)日：2024-04-30

申请号：US18219443

申请日：2023-07-07

申请人： Arti Vashist ,  Andrea D. Raymond ,  Prem Chapagain ,  Madhavan P. Nair ,  Carolyn D. Runowicz

发明人： Arti Vashist ,  Andrea D. Raymond ,  Prem Chapagain ,  Madhavan P. Nair ,  Carolyn D. Runowicz

IPC分类号： A61K31/765 ,  A61B5/00 ,  A61K9/107 ,  A61K36/55 ,  A61K47/36 ,  A61K47/38 ,  A61K49/00 ,  A61P35/00

CPC分类号： A61K31/765 ,  A61B5/0071 ,  A61K9/1075 ,  A61K36/55 ,  A61K47/36 ,  A61K47/38 ,  A61K49/0078 ,  A61P35/00

摘要： The present invention provides compositions and methods for selectively treating a cancer or tumor utilizing an effective amount of a vegetable oil-derived polyol or hydrogel particles comprising a vegetable oil-derived polyol. In some embodiments, the cancer is a gynecologic cancer, specifically an ovarian cancer. In other aspects, the present invention provides a method of targeting and imaging various tumors and/or tumor associated macrophages (TAMs).

公开(公告)号：US11969416B1

公开(公告)日：2024-04-30

申请号：US18057941

申请日：2022-11-22

申请人： Lumos Pharma, Inc.

发明人： Alpa B. Parikh ,  John C. McKew

IPC分类号： A61K31/438 ,  A61K9/20 ,  A61K9/28 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

CPC分类号： A61K31/438 ,  A61K9/2077 ,  A61K9/2846 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

摘要： The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.

公开(公告)号：US20240130991A1

公开(公告)日：2024-04-25

申请号：US18383641

申请日：2023-10-24

申请人： Balchem Corporation

发明人： Gideon Nyabuti Oenga

IPC分类号： A61K31/198 ,  A61K9/48 ,  A61K31/14 ,  A61K31/4172 ,  A61K47/12 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36

CPC分类号： A61K31/198 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4875 ,  A61K9/4891 ,  A61K31/14 ,  A61K31/4172 ,  A61K47/12 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36

摘要： Provided herein are rumen-protected compositions. The compositions include coated rumen-protected compositions which comprise a coating and a bioactive core comprising a physiologically active ingredient. The coating includes a chitosan organic salt, an emulsifier, and a fatty acid source. Further provided are rumen-protected pellet compositions, which may optionally comprise a coating. The pellet compositions include a bioactive core comprising a physiologically active ingredient and a chitosan organic salt. Further provided are methods of making the compositions and methods of delivering methionine to an animal.

公开(公告)号：US11963976B2

公开(公告)日：2024-04-23

申请号：US16642291

申请日：2018-09-05

申请人： National Cheng Kung University

发明人： Lynn L. H. Huang

IPC分类号： A61K31/727 ,  A61K9/00 ,  A61K31/728 ,  A61K47/36 ,  A61P9/10 ,  C07K14/49 ,  A61K45/06

CPC分类号： A61K31/727 ,  A61K9/0024 ,  A61K31/728 ,  A61K47/36 ,  A61P9/10 ,  C07K14/49 ,  A61K45/06

摘要： A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.